Eli Lilly highlights key R&D catalysts for 2018; Vernalis and Daiichi Sankyo work together on cancer targets
→ Eli Lilly has a few key R&D catalysts built in to its 2018 forecast, out today. Holding the line on an R&D budget that runs just north of the $5 billion mark, Lilly says they expect a regulatory decision on baricitinib for rheumatoid arthritis — after the FDA walked back a requirement on a new study — as well as the CGRP drug galcanezumab and a shot at a new indication for psoriatic arthritis for Taltz.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.